glp-1 small molecule agonist In the ACHIEVE-1 phase 3 trial, the oral small-molecule receptor orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes Oral GLP-1-Based Therapeutics in the
Pay in 4 interest-free payments of $5.73 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24



























